Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients

Reuters Staff  |  

March 23 (Reuters)—Roche Holding AG said on Monday it has received the U.S. Food and Drug Administration‘s clearance to test its rheumatoid arthritis treatment on patients hospitalized with severe pneumonia caused by the coronavirus.

The company said it was beginning a late-stage study to test the drug in what would be the first well-controlled study of the drug, Actemra (tocilizumab), on coronavirus patients.

ADVERTISEMENT
SCROLL TO CONTINUE

(Note: Reporting by Manas Mishra in Bengaluru; editing by Uttaresh.V.)

Related Articles

    Roche & Novartis Face Off in Biosimilar Drug Battle

    ZURICH (Reuters)—Switzerland’s biggest drugmakers are clashing over cheaper copies of pricey biotech drugs—one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche’s blood cancer drug Rituxan (rituximab) pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7…

    Enemy at the Gates: The Emerging Threat of COVID-19

    On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

    FDA Provides 2020 Rheumatology Drug Update

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

    Roche Gets Boost from FDA in Bid to Expand Uses for Actemra

    ZURICH (Reuters)—The U.S. Food and Drug Administration has granted breakthrough status to Roche’s rheumatoid arthritis medication Actemra (tocilizumab) for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine. Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries,…